ENROUTE Transcarotid Stent
Device Cardiology/Vascular Diseases
PDI 00811311020508
General payments
$10,000,756
Research payments
$2,850,801
Through program year 2024, $10,000,756 in general payments and $2,850,801 in research payments were reported against ENROUTE Transcarotid Stent (Cardiology/Vascular Diseases).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $2,794,532 | 10,431 |
| 2024 | Research | $982,143 | 311 |
| 2023 | General | $2,528,159 | 9,411 |
| 2023 | Research | $1,319,829 | 276 |
| 2022 | General | $2,588,978 | 9,349 |
| 2022 | Research | $485,516 | 69 |
| 2021 | General | $2,089,088 | 6,421 |
| 2021 | Research | $63,312 | 15 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 85 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
35,612 general · 671 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.